The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients.
central lymph node dissection
central lymph node metastasis
papillary thyroid microcarcinoma
risk factors
surgery
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
12
2021
accepted:
08
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
The aim of this study is to build a risk assessment system for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) of stage cN0 and to explore its application value in clinical practice. A total of 500 patients with PTMC who underwent thyroid operation from 2013 to 2015 in Ningbo First Hospital were selected as the model group. Independent risk factors related to CLNM in PTMC were analyzed and determined, and a risk assessment system for CLNM was preliminarily established. Furthermore, the clinicopathological data from 328 PTMC patients with the same conditions as the model group from 2016 to 2017 were further collected as the validation group to verify the diagnostic value of the risk assessment system. The risk assessment system was based on the score rating (score ≤ 5 was classified as low risk, 6-8 was classified as medium risk, and ≥9 was classified as high-risk). The area under the receiver operating characteristic curve (ROC) was 0.687 (95% CI: 0.635-0.783). According to the risk assessment system, 328 PTMC patients in the validation group were scored. Among the low-risk group, the moderate-risk group, and the high-group, 96.8%, 58.1%, and 43.2% were the CLNM (-) patients, and 3.1%, 41.9%, and 65.8% were CLNM (+) patients, respectively. The area under ROC was 0.837 (95% CI: 0.778-0.869). The risk assessment system in this study is of diagnostic value and can provide a theoretical foundation for intraoperative decision-making of prophylactic central neck dissection (pCND).
Sections du résumé
Background
The aim of this study is to build a risk assessment system for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) of stage cN0 and to explore its application value in clinical practice.
Methods
A total of 500 patients with PTMC who underwent thyroid operation from 2013 to 2015 in Ningbo First Hospital were selected as the model group. Independent risk factors related to CLNM in PTMC were analyzed and determined, and a risk assessment system for CLNM was preliminarily established. Furthermore, the clinicopathological data from 328 PTMC patients with the same conditions as the model group from 2016 to 2017 were further collected as the validation group to verify the diagnostic value of the risk assessment system.
Results
The risk assessment system was based on the score rating (score ≤ 5 was classified as low risk, 6-8 was classified as medium risk, and ≥9 was classified as high-risk). The area under the receiver operating characteristic curve (ROC) was 0.687 (95% CI: 0.635-0.783). According to the risk assessment system, 328 PTMC patients in the validation group were scored. Among the low-risk group, the moderate-risk group, and the high-group, 96.8%, 58.1%, and 43.2% were the CLNM (-) patients, and 3.1%, 41.9%, and 65.8% were CLNM (+) patients, respectively. The area under ROC was 0.837 (95% CI: 0.778-0.869).
Conclusions
The risk assessment system in this study is of diagnostic value and can provide a theoretical foundation for intraoperative decision-making of prophylactic central neck dissection (pCND).
Identifiants
pubmed: 35360071
doi: 10.3389/fendo.2022.843573
pmc: PMC8960455
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
843573Informations de copyright
Copyright © 2022 Wang, Sheng, Dai, Zhang, Song and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Thyroid. 2010 Jan;20(1):51-7
pubmed: 20067379
Front Endocrinol (Lausanne). 2021 Oct 29;12:763170
pubmed: 34777256
Gland Surg. 2020 Feb;9(Suppl 2):S153-S158
pubmed: 32175256
Front Endocrinol (Lausanne). 2021 Apr 07;12:638608
pubmed: 33897619
Gland Surg. 2021 Mar;10(3):1135-1146
pubmed: 33842257
World J Surg. 2002 Aug;26(8):1013-6
pubmed: 12045861
Front Endocrinol (Lausanne). 2021 Nov 16;12:772071
pubmed: 34867817
Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3801-4
pubmed: 25537818
Updates Surg. 2020 Dec;72(4):1135-1141
pubmed: 32333320
World J Surg. 2009 Mar;33(3):460-8
pubmed: 19123022
Head Neck. 2012 Nov;34(11):1591-6
pubmed: 22431167
G Chir. 2010 Mar;31(3):112-8
pubmed: 20426924
Sci Rep. 2020 Jan 20;10(1):710
pubmed: 31959758
Asian J Surg. 2016 Jul;39(3):131-6
pubmed: 26117203
World J Surg. 2012 Apr;36(4):748-54
pubmed: 22297627
Thyroid. 2013 Sep;23(9):1138-50
pubmed: 23470035
Oncol Lett. 2015 Oct;10(4):2559-2564
pubmed: 26622889
Surgery. 2008 Dec;144(6):980-7; discussion 987-8
pubmed: 19041007
Cancer. 2017 Feb 1;123(3):372-381
pubmed: 27741354
JAMA. 2006 May 10;295(18):2164-7
pubmed: 16684987
Int J Endocrinol. 2014;2014:385787
pubmed: 25214837
Laryngoscope. 2011 Jan;121 Suppl 1:S1-16
pubmed: 21181860
Head Neck. 2016 Apr;38 Suppl 1:E1568-74
pubmed: 26613871
Thyroid. 2012 Sep;22(9):911-7
pubmed: 22827494
Gland Surg. 2020 Jun;9(3):721-726
pubmed: 32775262
Zhonghua Wai Ke Za Zhi. 2008 Dec 15;46(24):1899-901
pubmed: 19134382
Gland Surg. 2020 Oct;9(5):1564-1572
pubmed: 33224832
Acta Oncol. 2010 May;49(4):454-9
pubmed: 20092427
Thyroid. 2004 Dec;14(12):1056-60
pubmed: 15650358
Surgery. 2008 Jun;143(6):743-9
pubmed: 18549890
Gland Surg. 2019 Jun;8(3):226-236
pubmed: 31328101
J Korean Med Sci. 2014 May;29(5):676-9
pubmed: 24851024
Cancer. 2006 Feb 1;106(3):524-31
pubmed: 16369995
Br J Surg. 2016 Jul;103(8):1020-5
pubmed: 27121346
Gland Surg. 2016 Dec;5(6):607-616
pubmed: 28149807
J Am Coll Surg. 2016 May;222(5):853-64
pubmed: 27113516
Surg Oncol. 2018 Jun;27(2):A21-A25
pubmed: 29525322